Literature DB >> 8699232

Infrequency of p53 gene mutations in ependymomas.

K L Fink1, E J Rushing, S C Schold, P D Nisen.   

Abstract

Ependymomas, which comprise 5% of central nervous system tumors, have not been extensively characterized genetically. The p53 tumor suppressor gene is frequently mutated in human cancer, and is important in the pathogenesis of other central nervous system (CNS) tumors. Chromosomal DNA corresponding to the p53 tumor suppressor gene was amplified by the polymerase chain reaction (PCR) from 31 archival ependymoma specimens. DNA was screened for the presence of p53 mutations by single strand conformational polymorphism (SSCP) analysis; samples with altered mobility were further tested for the presence of mutation by direct DNA sequence analysis. Of the 31 ependymomas tested, one contained a detectable DNA sequence change in the p53 gene. Sequencing revealed a silent mutation in exon 6, at codon 213, which represents a known p53 sequence polymorphism. These finding suggest that in contrast to many other human cancers, p53 mutation is not important in the pathogenesis or progression of ependymomas.

Entities:  

Mesh:

Year:  1996        PMID: 8699232     DOI: 10.1007/bf00177473

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

1.  Cancer. A deadly inheritance.

Authors:  B Vogelstein
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

2.  Involvement of the short arm of chromosome 1 in a myxopapillary ependymoma.

Authors:  J R Sawyer; M L Crowson; G J Roloson; W M Chadduck
Journal:  Cancer Genet Cytogenet       Date:  1991-07-01

3.  Ependymoma: a follow-up study of 101 cases.

Authors:  S J Mork; A C Loken
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

4.  Chromosome abnormalities in low-grade central nervous system tumors.

Authors:  C A Griffin; P P Long; B S Carson; H Brem
Journal:  Cancer Genet Cytogenet       Date:  1992-05

5.  Lack of histopathological correlation of malignant ependymomas with postoperative survival.

Authors:  G W Ross; L J Rubinstein
Journal:  J Neurosurg       Date:  1989-01       Impact factor: 5.115

6.  Ependymomas: a clinicopathologic study.

Authors:  C E Rawlings; F Giangaspero; P C Burger; D E Bullard
Journal:  Surg Neurol       Date:  1988-04

Review 7.  Epidemiology, cytogenetics, and molecular biology of brain tumors.

Authors:  A P Kyritsis; H Saya
Journal:  Curr Opin Oncol       Date:  1993-05       Impact factor: 3.645

Review 8.  Genetic alterations in glioma and medulloblastoma.

Authors:  B K Rasheed; S H Bigner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

Review 9.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

10.  Cytogenetic abnormalities in human ependymomas.

Authors:  M R Stratton; J Darling; P L Lantos; C S Cooper; B R Reeves
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

View more
  17 in total

Review 1.  Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies.

Authors:  Mandeep S Tamber; Krishan Bansal; Muh-Lii Liang; Todd G Mainprize; Bodour Salhia; Paul Northcott; Michael Taylor; James T Rutka
Journal:  Childs Nerv Syst       Date:  2006-09-02       Impact factor: 1.475

2.  Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups.

Authors:  Y Hirose; K Aldape; A Bollen; C D James; D Brat; K Lamborn; M Berger; B G Feuerstein
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.

Authors:  C Ebert; M von Haken; B Meyer-Puttlitz; O D Wiestler; G Reifenberger; T Pietsch; A von Deimling
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

4.  The TP53 p.R337H mutation is uncommon in a Brazilian cohort of pediatric patients diagnosed with ependymoma.

Authors:  Taciani de Almeida Magalhães; Kleiton Silva Borges; Graziella Ribeiro de Sousa; Silvia Regina Brandalise; Ana Luiza Seidinger; Carlos Alberto Scrideli; Sueli Mieko Oba-Shinjo; José Andrés Yunes; Luiz Gonzaga Tone
Journal:  Neurol Sci       Date:  2019-11-14       Impact factor: 3.307

5.  Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis.

Authors:  M J T Verstegen; D Troost S Leenstra; H Ijlst-Keizers; D A Bosch
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

6.  The expression of p73, p21 and MDM2 proteins in gliomas.

Authors:  Makoto Kamiya; Yoichi Nakazato
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

Review 7.  Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.

Authors:  Judith M de Bont; Roger J Packer; Erna M Michiels; Monique L den Boer; Rob Pieters
Journal:  Neuro Oncol       Date:  2008-08-01       Impact factor: 12.300

Review 8.  The genetic and epigenetic basis of ependymoma.

Authors:  Stephen C Mack; Michael D Taylor
Journal:  Childs Nerv Syst       Date:  2009-06-18       Impact factor: 1.475

Review 9.  Ependymoma.

Authors:  Charles Teo; Peter Nakaji; Patricia Symons; Vivienne Tobias; Richard Cohn; Robert Smee
Journal:  Childs Nerv Syst       Date:  2003-05-22       Impact factor: 1.475

10.  Immunohistochemical markers for prognosis of ependymal neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Valery Timirgaz
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.